10-K · August 14, 2026
Protagenic is a development-stage, single-segment biotechnology company with no product revenue and a strategy centered on PT00114, supported by an approximately $8 million annualized cost-reduction plan and a defined…
Earnings analysis · 10-Q
PTIX earnings analysis
Filed August 19, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include quarterly income statement, balance sheet, cash flow, or segment figures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the provided…
Read full summary
The extracted 10-Q text does not include quarterly income statement, balance sheet, cash flow, or segment figures, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed from the provided filing content. The principal negative signal is that, as of June 30, 2026, disclosure controls remained ineffective due to material weaknesses involving segregation of duties and financial-reporting review. Management has engaged an independent third party for remediation, while a potential recovery of at least $643,253 remains uncertain.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Third-party control remediation initiated
Management engaged an independent third party to enhance segregation of duties and identified additional controls to implement. The remediation plan is intended to address weaknesses identified as of June 30, 2026.
-
Potential legal recovery remains
The company is pursuing at least $643,253 from former clinical research organization Axiom Real-Time Metrics, although management is not forecasting recovery of any funds.
-
No material litigation currently pending
No legal proceedings, government actions, investigations, or claims are currently pending that management believes could reasonably be expected to have a material adverse effect on the business or financial condition.
What to watch
-
Disclosure controls remain ineffective
As of June 30, 2026, management concluded that disclosure controls and procedures were not effective because of material weaknesses in internal control over financial reporting.
-
Material accounting control weaknesses
The company lacks adequate segregation of duties and relies heavily on its Executive Chairman for almost every key financial duty, with access to materially all financial information. The filing also cites a limited level of multiple reviews in the financial reporting process.
-
Axiom recovery is uncertain
The company is pursuing at least $643,253 from Axiom Real-Time Metrics, but Axiom filed for receivership on July 11, 2025 and the company is not forecasting recovery of any funds.
Management's outlook
No quantitative revenue or EPS outlook is provided in the extracted 10-Q text. The filing states that there were no material changes to previously disclosed risk factors and provides no operating guidance.
Earlier filings 4
10-Q · March 9, 2026
Protagenic reported net income of $2,210,769 (EPS $1.14) for the three months ended December 31, 2025 versus a net loss of $(850,287) (EPS $(0.16)) in the prior-year quarter, driven primarily by a $3,112,041 change in…
10-Q · May 13, 2025
Protagenic reported a narrowed net loss of $1,440,005 (net loss per share $(2.75)) for Q1 2025 versus a $1,724,294 loss ($(5.44)/share) in Q1 2024, driven by lower R&D expense. The company has no revenue, cash declined…
10-Q · May 15, 2024
Protagenic reported a widening loss as the company ramped R&D spend tied to clinical development: net loss was $(1,724,294) (EPS $(0.39)) for the three months ended March 31, 2024 versus $(718,096) (EPS $(0.17)) in the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.